Press Releases

Media Inquiries - media@caredx.com

Date	Title and Summary	Additional Formats
Toggle Summary Nov 19, 2021	CareDx Named One of the Fastest-Growing Companies in North America on the Deloitte Technology Fast 500™ for the Third Consecutive Year SOUTH SAN FRANCISCO, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its	View HTML
Toggle Summary Nov 18, 2021	CareDx Enrolls First Patients in the Largest Digital Study in Transplant Using AlloCare to Assess Patient Outcomes TEAMMATE Study to Assess Impact in 4,000 Patients Across 100 Transplant Centers SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Nov 15, 2021	CareDx To Participate in Upcoming Conferences SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers,	View HTML
Toggle Summary Nov 10, 2021	CareDx Acquires MedActionPlan to Directly Support Patients with Better Adherence MedActionPlan adds a robust medication adherence platform to the CareDx digital suite, currently used in more than 100 hospitals and health systems SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the	View HTML
Toggle Summary Nov 04, 2021	University of Alabama Integrates CareDx’s TxAccess for Connection to Over 500 Community Practices TxAccess Supports and Accelerates Patients onto the Transplant Waitlist SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,	View HTML
Toggle Summary Nov 03, 2021	CareDx Focuses on Innovation in Transplant at ASN Kidney Week Two AlloSure abstracts will be featured at ASN, and CareDx will showcase innovations in transplantation at a virtual event on November 5 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,	View HTML
Toggle Summary Nov 01, 2021	CareDx Completes Orderly Management Transition SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Oct 28, 2021	CareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Oct 21, 2021	CareDx’s AlloSure Demonstrates Better Accuracy Than Current Standards of Care in Independent Kidney Transplant Study Landmark Longitudinal Study in Over 1,000 Transplant Patients Confirms AlloSure More Accurately Measures Organ Health SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and	View HTML
Toggle Summary Oct 19, 2021	CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon’s upcoming renal transplantation trials SOUTH SAN FRANCISCO, Calif. and IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused	View HTML